Cardiovascular risk factors affect hippocampal microvasculature in early AD
Tóm tắt
There is growing clinical and neuropathologic evidence suggesting that cognitive decline in early Alzheimer’s disease (AD) is aggravated by a synergistic relationship between AD and cerebrovascular disease associated with cardiovascular risk factors such as diabetes and hypertension. Here we used the stereologic “Space Balls” method to investigate the relationships between AD pathology and cardiovascular risk factors in postmortem human brains of patients with hypertension and diabetes in two groups — one consisting of cases with AD diagnosis and one of cases without. Hippocampal CA1 and CA3 microvasculature length density estimates were generated to characterize quantitatively the contribution of cardiovascular risk factors to the severity of neuropathologic changes. Our main finding is that the mean and variance of length density values in the AD group were significantly increased from the non-AD group, regardless of the absence or presence of a cardiovascular risk factor. An additional finding is that in the AD group without a risk factor, dementia severity correlated with amount of length density change in the CA1 field—this correlation did not exist in the AD groups with risk factors. Our findings suggest a role for cardiovascular risk factors in quantifiable change of hippocampal CA1 field microvasculature, as well as suggest a possible role of cardiovascular risk factors in altering microvasculature pathology in the presence of AD.
Tài liệu tham khảo
Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, et al. (1989) Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported. J Am Med Assoc 262: 2551–2556.
Rapaport E (1993) Secondary prevention of cardiovascular disease. Am J Geriatr Cardiol 2: 42–47.
Fair JM (2003) Cardiovascular risk factor modification: is it effective in older adults? J Cardiovasc Nurs 18: 161–168.
Hardy J (2006) A hundred years of Alzheimer’s disease research. Neuron 52: 3–13.
Schonheit B, Zarski R, Ohm TG (2004) Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. Neurobiol Aging 25: 697–711.
Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112: 389–404.
Buée L, Hof PR, Delacourte A (1997) Brain microvascular changes in Alzheimer’s disease and other dementias. Ann N Y Acad Sci 826: 7–24.
Giannakopoulos P, Gold G, Kovari E, von Gunten A, Imhof A, et al. (2007) Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience. Acta Neuropathol 113: 1–12.
Dannenberg AL, Garrison RJ, Kannel WB (1988) Incidence of hypertension in the Framingham Study. Am J Public Health 78: 676–679.
Skoog I, Gustafson D (2006) Update on hypertension and Alzheimer’s disease. Neurol Res 28: 605–611.
Kaplan NM (2002) Clinical Hypertension. Philadelphia: Lippincott Williams & Wilkins. 560 p.
Skoog I, Gustafson D (2003) Hypertension, hypertension-clustering factors and Alzheimer’s disease. Neurol Res 25: 675–680.
Dickstein DL, Walsh J, Brautigam H, Stockton SD, Jr., Gandy S, et al. (2010) Role of vascular risk factors and vascular dysfunction in Alzheimer’s disease. Mt Sinai J Med 77: 82–102.
Duron E, Hanon O (2008) Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag 4: 363–381.
Lin Y, Sun Z (2010) Current views on type 2 diabetes. J Endocrinol 204: 1–11.
Silvestre JS, Levy BI (2006) Molecular basis of angiopathy in diabetes mellitus. Circ Res 98: 4–6.
Brands AM, Biessels GJ, de Haan EH, Kappelle LJ, Kessels RP (2005) The effects of type 1 diabetes on cognitive performance: a metaanalysis. Diabetes Care 28: 726–735.
Allen KV, Frier BM, Strachan MW (2004) The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 490: 169–175.
Pasquier F, Boulogne A, Leys D, Fontaine P (2006) Diabetes mellitus and dementia. Diabetes Metab 32: 403–414.
Dooneief G, Marder K, Tang MX, Stern Y (1996) The Clinical Dementia Rating scale: community-based validation of “profound” and “terminal” stages. Neurology 46: 1746–1749.
Heyman A, Wilkinson WE, Hurwitz BJ, Helms MJ, Haynes CS, et al. (1987) Early-onset Alzheimer’s disease: clinical predictors of institutionalization and death. Neurology 37: 980–984.
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, et al. (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41: 479–486.
Zaccai J, Ince P, Brayne C (2006) Population-based neuropathological studies of dementia: design, methods and areas of investigation—a systematic review. BMC Neurol 6: 2.
Fillenbaum GG, van Belle G, Morris JC, Mohs RC, Mirra SS, et al. (2008) Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): the first twenty years. Alzheimers Dement 4: 96–109.
Shu SY, Ju G, Fan LZ (1988) The glucose oxidase-DAB-nickel method in peroxidase histochemistry of the nervous system. Neurosci Lett 85: 169–171.
Calhoun ME, Mouton PR (2001) Length measurement: new developments in neurostereology and 3D imagery. J Chem Neuroanat 21: 257–265.
Kreczmanski P, Schmidt-Kastner R, Heinsen H, Steinbusch HW, Hof PR, et al. (2005) Stereological studies of capillary length density in the frontal cortex of schizophrenics. Acta Neuropathol 109: 510–518.
Mouton PR, Gokhale AM, Ward NL, West MJ (2002) Stereological length estimation using spherical probes. J Microsc 206: 54–64.
Schmitz C, Hof PR (2005) Design-based stereology in neuroscience. Neuroscience 130: 813–831.
Brown WR, Moody DM, Thore CR, Anstrom JA, Challa VR (2009) Microvascular changes in the white mater in dementia. J Neurol Sci 283: 28–31.
van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, et al. (2008) Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke 39: 2712–2719.
Bell MA, Ball MJ (1981) Morphometric comparison of hippocampal microvasculature in ageing and demented people: diameters and densities. Acta Neuropathol 53: 299–318.
Hassler O (1965) Vascular changes in senile brains. A microangiographic study. Acta Neuropathol 5: 40–53.
Buée L, Hof PR, Bouras C, Delacourte A, Perl DP, et al. (1994) Pathological alterations of the cerebral microvasculature in Alzheimer’s disease and related dementing disorders. Acta Neuropathol 87: 469–480.
Bailey TL, Rivara CB, Rocher AB, Hof PR (2004) The nature and effects of cortical microvascular pathology in aging and Alzheimer’s disease. Neurol Res 26: 573–578.
Bouras C, Kovari E, Herrmann FR, Rivara CB, Bailey TL, et al. (2006) Stereologic analysis of microvascular morphology in the elderly: Alzheimer disease pathology and cognitive status. J Neuropathol Exp Neurol 65: 235–244.
Richard E, van Gool WA, Hoozemans JJ, An Haastert ES, Eikelenboom P, et al. (2010) Morphometric changes in the cortical microvascular network in Alzheimer’s disease. J Alzheimers Dis 22: 811–818.
Schmidt-Kastner R, Freund TF (1991) Selective vulnerability of the hippocampus in brain ischemia. Neuroscience 40: 599–636.
Petito CK, Pulsinelli WA (1984) Delayed neuronal recovery and neuronal death in rat hippocampus following severe cerebral ischemia: possible relationship to abnormalities in neuronal processes. J Cereb Blood Flow Metab 4: 194–205.
Kirino T (2000) Delayed neuronal death. Neuropathology 20Suppl: S95–97.
Calabresi P, Centonze D, Pisani A, Cupini L, Bernardi G (2003) Synaptic plasticity in the ischaemic brain. Lancet Neurol 2: 622–629.
Quintana P, Alberi S, Hakkoum D, Muller D (2006) Glutamate receptor changes associated with transient anoxia/hypoglycaemia in hippocampal slice cultures. Eur J Neurosci 23: 975–983.
Schuff N, Matsumoto S, Kmiecik J, Studholme C, Du A, et al. (2009) Cerebral blood flow in ischemic vascular dementia and Alzheimer’s disease, measured by arterial spin-labeling magnetic resonance imaging. Alzheimers Dement 5: 454–462.
Hirao K, Ohnishi T, Hirata Y, Yamashita F, Mori T, et al. (2005) The prediction of rapid conversion to Alzheimer’s disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage 28: 1014–1021.
Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, et al. (2005) Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 234: 851–859.
Mariani E, Polidori MC, Cherubini A, Mecocci P (2005) Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci 827: 65–75.
Dyrks T, Dyrks E, Masters CL, Beyreuther K (1993) Amyloidogenicity of rodent and human beta A4 sequences. FEBS Lett 324: 231–236.
Troncoso JC, Costello A, Watson AL, Jr., Johnson GV (1993) In vitro polymerization of oxidized tau into filaments. Brain Res 613: 313–316.
Yang SP, Bae DG, Kang HJ, Gwag BJ, Gho YS, et al. (2004) Coaccumulation of vascular endothelial growth factor with betaamyloid in the brain of patients with Alzheimer’s disease. Neurobiol Aging 25: 283–290.
Brickman AM, Reitz C, Luchsinger JA, Manly JJ, Schupf N, et al. (2010) Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. Arch Neurol 67: 564–569.
McCall AL (1992) The impact of diabetes on the CNS. Diabetes 41: 557–570.
Reitz C, Tang MX, Manly J, Mayeux R, Luchsinger JA (2007) Hypertension and the risk of mild cognitive impairment. Arch Neurol 64: 1734–1740.
Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, et al. (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. J Am Med Assoc 277: 813–817.
Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, et al. (2000) Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging 21: 57–62.
Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, et al. (1997) Association between features of the insulin resistance syndrome and Alzheimer’s disease independently of apolipoprotein E4 phenotype: cross sectional population based study. Br Med J 315: 1045–1049.
Gispen WH, Biessels GJ (2000) Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 23: 542–549.
Kumari MV, Hiramatsu M, Ebadi M (2000) Free radical scavenging actions of hippocampal metallothionein isoforms and of antimetallothioneins: an electron spin resonance spectroscopic study. Cell Mol Biol 46: 627–636.
Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I (2002) Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 8: 1390–1397.
Schneider JA, Bennett DA (2010) Where vascular meets neurodegenerative disease. Stroke 41: S144–S146.
Mungas D, Reed BR, Ellis WG, Jagust WJ (2001) The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease. Arch Neurol 58: 1243–1247.
Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD (1999) Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer’s disease. Lancet 354: 919–920.
Jellinger KA (2002) Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 109: 813–836.
Zekry D, Duyckaerts C, Moulias R, Belmin J, Geoffre C, et al. (2002) Degenerative and vascular lesions of the brain have synergistic effects in dementia of the elderly. Acta Neuropathol 103: 481–487.
Beeri MS, Silverman JM, Davis KL, Marin D, Grossman HZ, et al. (2005) Type 2 diabetes is negatively associated with Alzheimer’s disease neuropathology. J Gerontol A Biol Sci Med Sci 60: 471–475.
Heitner J, Dickson D (1997) Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. Neurology 49: 1306–1311.
Sonnen JA, Larson EB, Brickell K, Crane PK, Woltjer R, et al. (2009) Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 66: 315–322.
Nelson PT, Smith CD, Abner EA, Schmitt FA, Scheff SW, et al. (2009) Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim Biophys Acta 1792: 454–469.
van den Berg E, Reijmer YD, de Bresser J, Kessels RP, Kappelle LJ, et al. (2010) A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus. Diabetologia 53: 58–65.
Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, et al. (2001) Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. Br Med J 322: 1447–1451.
Raz N, Lindenberger U, Rodrigue KM, Kennedy KM, Head D, et al. (2005) Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. Cereb Cortex 15: 1676–1689.
Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH (1994) Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb Cortex 4: 138–150.
Giannakopoulos P, Hof PR, Savioz A, Guimon J, Antonarakis SE, et al. (1996) Early-onset dementias: clinical, neuropathological and genetic characteristics. Acta Neuropathol 91: 451–465.
Vallet PG, Guntern R, Hof PR, Golaz J, Delacourte A, et al. (1992) A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer’s disease. Acta Neuropathol 83: 170–178.
Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88: 1337–1342.